Document is current
Any future updates will be listed below
-
Authors
Shiraishi, N. https://orcid.org/0000-0003-4089-1816
Sakata, M. https://orcid.org/0000-0002-5358-5263
Toyomoto, R. https://orcid.org/0000-0003-1125-3145
Yoshida, K. https://orcid.org/0000-0003-4475-8043
Luo, Y. https://orcid.org/0000-0002-5271-5126
Nakagami, Y. https://orcid.org/0000-0001-7495-8957
Tajika, A. https://orcid.org/0000-0003-3926-8867
Watanabe, T. https://orcid.org/0000-0001-5477-187X
Sahker, E. https://orcid.org/0000-0002-4269-4800
Uwatoko, T. https://orcid.org/0000-0002-7917-9060
Shimamoto, T. https://orcid.org/0000-0001-7661-6299
Iwami, T. https://orcid.org/0000-0002-4150-7065
Furukawa, T. A. https://orcid.org/0000-0003-2159-3776
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (21K03049, 18K18643)
Suzuken Memorial Foundation
KDDI Foundation
Pfizer Health Research Foundation
World Health Organization Centre for Health Development (WHO Kobe Centre – WKC: K22001)
Japan Agency for Medical Research and Development (dk0307085)
JST-Mirai Program (JPMJMI20D6)
World Health Organization Mental Health Research (2021/HQ/WKC/0013)
- License Information
-
More Information
Article History
Received: 14 April 2023
Accepted: 22 September 2023
First Online: 10 October 2023
Declarations
:
: We obtained written informed consent from students who participated in the HCT (No. UMINCTR-000031307). The trial data were used with the approval of the Ethics Committees of Kyoto University Graduate School of Medicine (No. C1357) and Nagoya City University Graduate School of Medical Sciences (No. 46-19-0006). The Helsinki Declaration was followed in implementing the trial, and all methods were conducted in accordance with relevant guidelines and regulations.
: Not applicable.
: NS received lecture fees from Mochida Pharma and Sumitomo Pharma for work not associated with this study. MS received personal fees from SONY. TAF received grants and personal fees from Mitsubishi-Tanabe, personal fees from SONY, and personal fees from Shionogi that are outside the submitted work; TAF also has a patent pending (2020-548587) concerning a smartphone CBT app and owns intellectual properties for a Kokoro-app licensed to Mitsubishi-Tanabe. All other authors have no competing interests to declare.
